Private equity firm Olympus is in the process of selling a 5% stake in Aster DM Healthcare through a block deal valued at approximately $100 million, according to sources who spoke to Moneycontrol on the condition of anonymity. The deal includes an option to increase the sale to an additional 5% stake, potentially making it a $200 million transaction if Olympus decides to sell its entire remaining 10.1% stake in the company.

The floor price for the proposed sale has been set at ₹331 per share, which represents a 7.1% discount to the last closing price. Kotak Securities is advising on the deal. As of the latest exchange filings, Olympus Capital Asia Investments Ltd holds a 10.10% stake in Aster DM Healthcare.

In March, Olympus sold around 9.8% of its stake in Aster DM Healthcare for approximately $235 million through a block deal.

On September 20, 2022, Moneycontrol reported that Aster DM Healthcare had initiated a significant internal reorganization to unlock value and had engaged Gulf funds and sovereign funds to sell a stake in its Middle East business. In November, Aster DM Healthcare approved the sale of its Middle East (GCC) business to Alpha GCC Holdings Ltd for an equity value of $1 billion.

The promoter family currently holds a 41.88% stake in Aster DM Healthcare. Following the announcement of the GCC deal, Dr. Azad Moopen, Chairman of Aster DM Healthcare, indicated openness to selling a majority stake in the India business if a suitable strategic partner is found. He mentioned the possibility of joint control rather than a majority stake, emphasizing the importance of strategic benefits and collaborative opportunities.

This strategic maneuvering reflects Olympus’s continued interest in optimizing its investment in Aster DM Healthcare while aligning with the healthcare company's broader goals of unlocking value and expanding its footprint in key markets.